Targeted Oncology1h
Axatilimab Leads to Strong Responses in Heavily Pretreated cGVHD
In terms of response, it met its primary end point in all 3 doses. 1 The ORR was 50% or higher [in all 3 groups]. The dose of ...
CURE6h
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Le Lézard9h
Signal12 Achieves FDA Alignment, Accelerating Pro-oculartm Towards Phase 3 Clinical Trials for Ocular Graft-versus-Host Disease
Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today ...
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patients
Graft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as foreign and rejects them.